Harold C. Simmons Comprehensive Cancer Center

Researchers

• SHSamer Al Hadidi

Running trials

• Recruiting

  A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma

  NCT05440708· Phase 1/2· Tvardi Therapeutics, Incorporated· Source

• Recruiting

  A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

  NCT05651932· Phase 1· K36 Therapeutics, Inc.· Source

• Active, not recruiting

  Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

  NCT05183035· Phase 3· PedAL BCU, LLC· Source

• Recruiting

  GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC

  NCT04864054· Phase 1/2· Eureka Therapeutics Inc.· Source

• Active, not recruiting

  A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies

  NCT03888105· Phase 2· Regeneron Pharmaceuticals· Source

• Active, not recruiting

  Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

  NCT02598661· Phase 2/3· Geron Corporation· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Liver and biliary tract cancer2 recruiting
• Multiple myeloma1 recruiting

Closed trials

• Completed

  Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma

  NCT04919642· Phase 2· TransThera Sciences (Nanjing), Inc.· Source

• Completed

  A Study of SEA-CD40 Given With Other Drugs in Cancers

  NCT04993677· Phase 2· Seagen Inc.· Source

• Terminated

  An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas

  NCT05011058· Phase 2· Viracta Therapeutics, Inc.· Source

• Completed

  IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML

  NCT04372433· Phase 1· Immune-Onc Therapeutics· Source

• Terminated

  Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms

  NCT03878199· Phase 1/2· Ohio State University Comprehensive Cancer Center· Source

• Completed

  Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)

  NCT03036488· Phase 3· Merck Sharp & Dohme LLC· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Kidney cancer48 works · 0 trials
• Multiple myeloma46 works · 1 trial
• Myelodysplastic syndromes10 works · 1 trial